Nonadherence to Noncancer Medication Schedules Predicts Adherence to Adjuvant Hormone Therapy for Breast Cancer
Patients who do not adhere to their medication schedules for chronic conditions prior to a breast cancer diagnosis were twice as likely to skip oral adjuvant hormonal therapy.
Employing a prone position during preoperative breast magnetic resonance imaging might introduce error.
Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.
The addition of a patient navigation component to a population-based IT system boosted screening rates for breast cancer, cervical cancer, and colorectal cancer in patients at high risk for nonadherence.
Trastuzumab-related cardiotoxicity was far lower in Taiwanese women with breast cancer compared with previously published results, according to recent study data.
New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
Researchers demonstrate how breast cancer cells invade bone marrow, where they escape chemotherapy and hormonal therapies that would otherwise eliminate the cancer cells.
A gene expression pattern in the noncancerous tissues surrounding estrogen receptor-positive breast cancer is associated with lower 10-year survival rates.
Patient Stress Level Influences Best Type of Couples' Therapy for Patients With Breast Cancer and Their Partners
Distressed patients with breast cancer benefit most from a couple-focused supportive group therapy, while less distressed patients benefit more from a structured, skills-based, couples-focused group therapy.
Following a healthy lifestyle could reduce the risk of developing breast cancer for women already at high risk for the disease due to genetic risk and family history.
The drug denosumab, which blocks a bone gene, may also prevent breast cancer caused by a BRCA1 mutation. This already approved drug could be available quickly, and would be the first drug for breast cancer prevention.
The incidence of cardiovascular events was down for patients with non-metastatic breast cancer that exercise.
Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.
A substantial and independent association between individual provider, the treatment center, and type of breast surgery among elderly women with breast cancer suggests the presence of physician and institutional biases. That is the conclusion of a Medicare claims database review presented at the 2016 ASCO Annual Meeting.
"Routine use of ALND should be abandoned." That's the conclusion based on 10-year survival data from the ACOSOG Z0011 randomized study comparing sentinel lymph node dissection alone to ALND in women with clinical T1-2 N0 M0 breast cancer and a positive sentinel node presented at the 2016 ASCO Annual Meeting.
The genetically engineered epothilone analog, utidelone, in combination with capecitabine significantly improved progression-free survival and objective response rates in patients with metastatic breast cancer who were heavily pretreated, compared with capecitabine alone, results of a phase 3 trial presented at the 2016 ASCO Annual Meeting have shown.
Tailored dose-dense chemotherapy significantly improved event-free survival and also showed efficacy in relapse-free and overall survival compared with standard adjuvant chemotherapy in patients with high-risk breast cancer, according to results of the phase 3 PANTHER study reported at the 2016 ASCO Annual Meeting.
Interim joint analysis of the ABC Trials showed invasive disease-free survival was significant for superiority of anthracycline/taxane-based chemotherapy regimens (TaxAC) relative to docetaxel plus cyclophosphamide, according to study results presented at the 2016 ASCO Annual Meeting.
Palbociclib Plus Fulvestrant Provides Significant Benefit in Hormone Receptor-Positive Metastatic Breast Cancer
ESR1 mutations detected in plasma circulating tumor DNA were identified in a high percentage of patients with hormone receptor-positive metastatic breast cancer, confirming an important role in endocrine resistance, according to an analysis of data from the phase 3 PALOMA-3 reported at the 2016 ASCO Annual Meeting.
ESR1 Mutations Predict Worse Outcome in HR-positive Metastatic Breast Cancer Treated with Aromatase Inhibitors
The presence of circulating ESR1 somatic mutations at disease progression in patients with HR-positive metastatic breast cancer treated with first-line AIs represent a strong and independent poor prognostic value for overall survival but no predictive value, a study presented at the 2016 ASCO Annual Meeting has found.
A cocktail of 3 drugs shrank triple-negative breast cancer (TNBC) by killing off cancer cells and halting new tumor growth, a new study conducted in mice and lab-grown human cells has shown.
Abemaciclib, an investigational cancer therapeutic, showed durable clinical activity as a continuous single-agent therapy, according to results of a phase 1 trial with 5 tumor-specific cohorts.
Scientists discovered the compound eCF506. This compound was more effective than existing medicines at targeting breast cancer cells because it more selectively inhibited SRC tyrosine kinase.
A potential cancer therapy with a unique strategy to block the mTOR molecule has been designed. This new mTOR-inhibiting compound reduced the size of tumors resistant to earlier-generation mTOR inhibitors.
Vitamin D and androgen receptor-targeted therapy successfully reduced growth and induced death of cancerous cells in a cell culture model of triple-negative breast cancer.
Training Patients With Breast Cancer to Achieve Prolonged Breath Holds Could Improve Targeted Radiotherapy
Patients with breast cancer can be trained to achieve a breath hold lasting more than 5 minutes, allowing for targeted administration of radiotherapy with a single dose per daily session that can minimize damage to surrounding tissues.
A new drug candidate reduced the growth of tumors in a mouse model of triple negative breast cancer (TNBC) by targeting the RNA, or expression, of a gene only expressed in the diseased cells.
Both automated and clinical assessments of breast density are associated with breast cancer risk.
No Clinical Benefit to Expanding Gene Panel Beyond Ovarian and Breast Cancer Genes in High-risk Women
Expanding a panel of tested genes beyond the known breast and ovarian cancer-specific genes in patients with breast and ovarian cancer did not confer any clinical benefit.
Combining 2 existing chemotherapy drugs, a DNMT1 inhibitor and a histone deacetylase inhibitor, reduced the numbers of cancer stem cells and improved survival in a mouse model.
Researchers examined possible correlations between complementary and alternative medicine and delayed initiation of clinically indicated chemotherapy among patients with early-stage breast cancer.
Disparities in BRCA1/2 testing in black and white women is attributable to differences in physician recommendations, according to a recent study.
Patients undergoing treatment for breast cancer with trastuzumab-containing regimens need to be monitored for heart damage regardless of age.
For women younger than 45 years with early stage breast cancer that has not spread to the lymph nodes, opting for breast-conserving therapy with RT was associated with higher risk of local recurrence over 20 years compared with mastectomy and no RT.
Amplification of the JAK2 gene frequently occurs in triple-negative breast cancer (TNBC), suggesting that specific inhibitors of JAK2 should be investigated in TNBC.
Delayed radiation therapy (RT) after surgery significantly increased the risk of recurrent disease in women treated for very early breast cancer.
Risk for Fatal Cardiovascular Events Not Increased in Patients With Breast Cancer Taking Aromatase Inhibitors
Risk of the most serious cardiovascular events, cardiac ischemia and stroke, were not increased in breast cancer patients taking aromatase inhibitors compared with tamoxifen users.
Disparities in the gut microbiome between healthy people and women with estrogen-driven breast cancer may indicate possible biomarkers based on the microbiome that could help to mitigate the risk of certain cancers.
Combining trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab for patients with HER2-positive invasive breast cancer.
[Breast Cancer: Basic and Clinical Research] The review examines the standard systemic and future treatment options in metastatic triple-negative breast cancer.
Comprehensive patient education that includes information on breast reconstruction, with photos, can help women with breast cancer make more informed decisions about their treatment options.
Postmenopausal women who stayed on a low fat diet for an extended time had a reduced risk of death from invasive breast cancers, according to clinical trial data.
Prophylactic nipple-sparing mastectomy is as effective at preventing breast cancer as more invasive surgeries, according to a multi-institution study.
The BRCA1 mutation may speed the aging of a woman's ovaries,according to a recent report.
Longer survival was achieved with stereotactic radiosurgery (SRS) alone than with whole-brain radiation therapy (WBRT) in patients with fewer than 4 brain metastases from NSCLC or breast cancer.
Anthracycline chemotherapy, such as doxorubicin and daunorubicin, is not associated with lasting cognitive decline among breast cancer survivors.
The risk of the most serious cardiovascular events, including cardiac ischemia and stroke, was not higher for breast cancer survivors who received an aromatase inhibitor (AI) compared with tamoxifen users.
Significant weight loss through calorie restriction, but not moderate weight loss through a low-fat diet, was linked to reduced breast cancer growth in a preclinical study.
A study examined the relation between various forms of breast cancer therapies and risk of congestive heart failure.
A biosimilar agent to pegfilgrastim was therapeutically equivalent and comparable to the reference agent in terms of efficacy and safety in the prevention of chemotherapy-induced neutropenia in patients with early stage breast cancer receiving chemotherapy.
Latina women in the United States nearly doubled their rate of screening for breast cancer after visits from a health-promoting promotora.
Neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel with respect to progression-free survival as first-line treatment.
[Breast Cancer: Targets and Therapy] This research examines using Astym treatment to increase mobility after mastectomy.
The first widely useful standard for magnetic resonance imaging (MRI) of the breast has been developed by the NIST.
Women with breast cancer who used acupuncture plus enhanced self-care to manage their hot flashes were better able to manage their symptoms.
Risk-reducing mastectomy (RRM) can increase life expectancy and be cost effective in women up to age 60 years with ovarian cancer as carriers of a BRCA mutation.
The amount of calcium in the arteries of the breast, readily visible on digital mammography, is linked to the level of calcium buildup in the coronary arteries.
For patients with stage I to III HER2-positive breast cancer, the monoclonal antibody trastuzumab is central to their adjuvant therapy.
German Study Confirms Accuracy of Multigene Test Predictions of Safe Omission of Chemotherapy for Breast Cancer
A multigene test can identify patients with early stage breast cancer who do not need chemotherapy and who will be alive 5 years after diagnosis.
Scientists are developing a pill that illuminates only cancerous tumors, improving on current methods that can identify tumors but cannot conclusively determine whether they are cancerous
Population-based screening for breast cancer with universal biennial mammography resulted in a substantial reduction in breast cancer deaths, while risk-based biennial mammography resulted in only a modest benefit.
Improvements seen in climacteric symptoms and quality of life measures when acupuncture was employed.
Researchers identified a cancer-causing gene triggered by alcohol use, providing a link between alcohol and breast cancer in cell-based research.
Disparities Related to Race, Insurance, and Facility Type Affect Use of Genetic Assay in Breast Cancer
Use and clinical implications of a test commonly used to predict the aggressiveness of early stage ER-positive breast cancer is influenced by patient's race, insurance, and type of facility.
Prolonged nightly fasting may reduce the risk of recurrence for patients with breast cancer.
Optimal risk stratification differs between male and female breast cancers. Outcomes for male patients with breast cancer were not significantly correlated with histologic grade, unlike for female patients.
Treatment with lapatinib and trastuzumab before surgery and chemotherapy led to significant shrinkage or disappearance of the tumors in approximately 25% of women with HER2-positive breast cancer.
A tailored high-dose oral vitamin D supplementation safely allows a higher proportion of patients to achieve a normalized vitamin D level.
The HER2 peptide AE37 vaccine did not demonstrate a benefit in patients with breast cancer with any degree of HER2 expression.
Partial breast radiotherapy was noninferior to whole breast radiotherapy in regard to local recurrence in women with low-risk early breast cancer.
Diabetes treatments, such as diet or pills (eg, metformin), decrease mammographic density, whereas insulin may increase mammographic density.
Cyclin D1/CDK4 inhibitor treatment overcame resistance to targeted therapy in transgenic mouse models, cell cultures, and human tissue samples of HER2-positive breast cancer.
Dose-dense adjuvant chemotherapy (every 2 weeks) offers improved survival without increasing the risk of treatment-induced early menopause compared with the standard interval (every 3 weeks) chemotherapy for premenopausal women with breast cancer.
Germline mutations to the RECQL gene were identified in 0.5% of patients with familial breast cancer in a Chinese population.
Early MRI-based screening may reduce breast cancer mortality among women treated with radiation therapy for Hodgkin lymphoma.
Deficiency in vitamin D resulted in breast cancer tumors that grew faster and were more likely to metastasize, according to a recent study using mouse and cell culture models. The study also demonstrated a correlation between serum vitamin D levels and ID1.
Early changes in patient-reported outcomes during aromatase inhibitor (AI) therapy were associated with treatment discontinuation.
Symptoms of posttraumatic stress disorder (PTSD) develop in a majority of patients with breast cancer, and these symptoms persist for at least a year for most.
[Biomarkers in Cancer] This research examines the emerging role of genomic rearrangements in breast cancer, with a particular focus on fusion genes, and explores the therapeutic value of such rearrangements and their significance as predictive and prognostic biomarkers.
Eating processed meats such as bacon and sausage may increase the risk for breast cancer in Latinas, while the same association was not found in white women.
Patients with breast cancer increasingly opt to have the healthy breast removed, despite limited benefit.
Adding Palbociclib to Fulvestrant Improves Progression-free Survival in Select Women With Metastatic Breast Cancer
Progression-free survival was significantly and consistently improved when palbociclib was added to fulvestrant, compared with placebo and fulvestrant, for women with stage IV breast cancer that is hormone-receptor-positive and HER2-negative.
In women undergoing postmastectomy breast reconstruction with their own tissue, a specific type of muscle-sparing abdominal tissue reduced complications and improved some aspects of quality of life.
Adrenaline acted on breast cancer cells via the cell surface beta2-adrenoceptor to promote disease growth and invasion, suggesting that beta-blockers might be helpful as adjuvant therapy for patients with aggressive breast cancer.
Limited radiotherapy effective after low-risk tumors are removed, but questions remain.
No significant changes in global longitudinal strain (GLS) or cardiac biomarkers occurred in HER2-positive breast cancer.
Women with the HER2-enriched type of HER2-positive breast cancer had the highest rate of immune response to treatment with trastuzumab, with a significant increase after just 1 dose of the drug.
Model Demonstrates Benefits of MRI Screening for Breast Cancer in Survivors of Childhood Hodgkin Lymphoma
Female survivors of childhood Hodgkin lymphoma (HL) who received chest radiation can reduce their risk of breast cancer through early screening.
A new cell culture scaffold system supported human mammary tissue growth from patient-derived cells, allowing researchers to replicate human breast environment conditions to study breast development and the initiation and progression of breast cancer.
Modest weight loss can reduce the likelihood of comorbid conditions in breast cancer survivors.
An analysis of test results can help women who won't benefit from additional treatment avoid potential side effects.
A new analysis method for magnetic resonance imaging (MRI) data appears to reliably determine whether patients would need hormonal treatment only or also need chemotherapy.
High neutrophil to lymphocyte ratio (NLR) is linked to worse prognosis in Caucasian patients with early breast cancer.
Ultrasound may have a better incremental breast cancer detection rate than tomosynthesis in mammography-negative dense breasts.
Disparities in some cancer mortality rates between African Americans and whites in the United States have decreased, but these differences remain in colorectal and breast cancers.
Cancer metastasis is dynamically regulated by cancer-associated fibroblasts (CAFs), a cancer-promoting component in the tumor microenvironment. Eliminating the CAFs after 10 days dramatically increases the risk of the primary tumor metastasis to the lungs and bones in a mouse model.
Choice for contralateral prophylactic mastectomy (CPM) was associated with an improvement in breast satisfaction and psychosocial well-being.
The addition of palbociclib to fulvestrant was associated with significant and consistent improvement in progression-free survival.
A gene previously thought only to be expressed in the brain, GABAA receptor alpha3 (Gabra3), promotes breast cancer migration, invasion, and metastasis.
Approximately 1 in 4 survivors of breast cancer suffers from severe fatigue.
Among women age 40 years or younger, rates of genetic testing for BRCA1 and BRCA2 mutations have increased, according to a recent study.
- Baseline PSA Levels in Midlife Could Predict Risk of Lethal Prostate Cancer
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Up to One-Quarter of Patients With Lung Cancer Ineligible for Immunotherapy
- Imaging Technique Is Predictive of Immunotherapy Response in Non-Small Cell Lung Cancer
- Blinatumomab Improves Overall Survival in Acute Lymphoblastic Leukemia
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Triple-Drug Therapy Produces Response in Triple-Negative Breast Cancer, Mouse Study Shows
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Study Supports Increased Role for Surgery in Multimodality Therapy for Early Stage SCLC
- Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL
- Nonadherence to Noncancer Medication Schedules Predicts Adherence to Adjuvant Hormone Therapy for Breast Cancer
- Premedication With Antiemetic Improves Length of Stay and Readmissions for a Liver Cancer Procedure
- Aspirin Use Found to Prevent Cholangiocarcinoma
- Focal Laser Ablation Feasible and Safe for Treatment of Prostate Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|